Patents by Inventor Qingsong GUO

Qingsong GUO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240058463
    Abstract: A B7-H3 targeting antibody-drug conjugate, and a preparation method therefor and use thereof. Provided is the antibody-drug conjugate as shown in formula I. The compound has a good targeting property, good inhibitory effect on tumor cells positively expressing B7-H3, and good druggability and safety. The present antibody-drug conjugate has an inhibitory effect against B7-H3, and also a good inhibitory effect against at least one of NCI-N87, A375, LN-229, PA-1, MDA-MB-468, Calu-6 and HS-700T cells.
    Type: Application
    Filed: December 18, 2020
    Publication date: February 22, 2024
    Inventors: Qingsong GUO, Yijun SHEN, Tong YANG, Bin BAO, Bei GAO, Fang WU, Jun XU
  • Publication number: 20240050584
    Abstract: A TROP2 targeting antibody-drug conjugate, and a preparation method and use therefor. The antibody-drug conjugate is shown in formula I. Said type of compound has a good targeting property, a good inhibitory effect on tumor cells positively expressing TROP2, and good druggability and high safety. The present antibody drug conjugate has an inhibitory effect on TROP2, and also a good inhibitory effect on at least one of NCI-N87, MDA-MB-468 and BXPC3 cells.
    Type: Application
    Filed: December 18, 2020
    Publication date: February 15, 2024
    Inventors: Qingsong GUO, Yijun SHEN, Tong YANG, Bin BAO, Bei GAO, Fang WU, Jun XU
  • Publication number: 20240016949
    Abstract: An antibody-drug conjugate, and an intermediate thereof, a preparation method therefor, and an application thereof. Provided is an antibody-drug conjugate as represented by formula I. The compound has good targetability, has a good inhibitory effect on HER3-positive tumor cells, and has good druggability and high safety. The antibody-drug conjugate has an inhibitory effect on HER3, has an inhibitory effect on SK-BR-3 and SW620 cells, and also has a good inhibitory effect on at least one of 22Rv1, LNCaP, NCI-H820, OVCAR-8, and HCC827 cells.
    Type: Application
    Filed: December 4, 2020
    Publication date: January 18, 2024
    Inventors: Qingsong GUO, Yijun SHEN, Tong YANG, Bin BAO, Bei GAO, Fang WU, Jun XU
  • Patent number: 11845896
    Abstract: A structural stabilizer for a fiber and proppant complex to enhance proppant migration and placement in a fractured well during propping and a preparation method thereof are provided. The structural stabilizer consists of: water, inorganic salt, kaolinite, nitrogen-doped modified graphene oxide, anionic surfactant, non-ionic alkyl polyglucoside, and polyacrylamide. The structural stabilizer improves bonding between a proppant and a fiber when slick water is used in stimulated reservoir volume (SRV) fracturing, prevents separation of the fiber and the proppant during migration, thereby reducing escape rate of the fiber from the fiber and proppant complex.
    Type: Grant
    Filed: July 13, 2023
    Date of Patent: December 19, 2023
    Assignees: Chengdu LEPS Technology Co., Ltd, Southwest Petroleum University
    Inventors: Jianchun Guo, Shan Ren, Hao Yang, Yingxian Ma, Kun Wang, Jiyu Wang, Cong Lu, Jiapeng Zhang, Zhihong Zhao, Shaobin Zhang, Qianli Lu, Qingsong Guo, Su Diao, Chi Chen, Xin Lei, Mingyuan Zhou, Chaojun Tang
  • Publication number: 20220233708
    Abstract: Disclosed are an antibody-drug conjugate (ADC), an intermediate thereof, a preparation method therefor and an application thereof. The present invention provides an ADC. A structural general formula thereof is Ab-(L3-L2-L1-D)m. The ADC has better biological activity, stability, and uniformity, has reduced toxic and side effects, and has a faster release rate of enzyme cutting in tumor cells. The use of the novel ADC can achieve a wide application of a cytotoxic drug particularly camptothecin in the field of ADCs in treating tumor patients resistant to microtubule ADC.
    Type: Application
    Filed: June 5, 2020
    Publication date: July 28, 2022
    Inventors: Bin BAO, Qingsong GUO, Bei GAO, Yifan ZHANG, Xuefei QIU, Tong YANG, Yijun SHEN, Wenbo ZHANG, Wei LV, Lei WANG
  • Publication number: 20220226334
    Abstract: An application of an antibody conjugate in the preparation of a drug for treating CD30 positive tumors, which is characterized in that: the antibody conjugate is F0002-ADC; the general formula of the structural thereof is Ab-Lm-Yn; and the CD30-positive tumors are CD30-positive tumors that express a multidrug resistance gene 1. In addition, a pharmaceutical combination and a pharmaceutical composition containing the antibody conjugate, which may be applied to the preparation of a drug used for treating CD30-positive tumors.
    Type: Application
    Filed: May 21, 2019
    Publication date: July 21, 2022
    Inventors: Yijun SHEN, Tong YANG, Yanjun LIU, Qingsong GUO, Xuemei CAO, Hua LI, Bei GAO, Guanghao WU, Likai MENG, Yanbo GAO, Yang ZHU
  • Publication number: 20220017620
    Abstract: An anti-B7-H3 antibody, a preparation method therefor, a conjugate and an application thereof. The anti-B7-H3 antibody comprises a complementarity determining region: one or more of heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3, and/or one or more of light chain CDR1, light chain CDR2, and light chain CDR3. A sequence of the complementarity determining region is as described in the specification. The anti-B7-H3 antibody is a fully human antibody, has a unique antigen binding epitope, and can specifically bind B7-H3 antigen on tumor cells. Moreover, the antibody can rapidly internalize into cells after binding to tumor cells, and can be used for ADC drug development to obtain better anti-tumor activity and efficacy to achieve the purpose of treating cancers.
    Type: Application
    Filed: November 8, 2019
    Publication date: January 20, 2022
    Inventors: Qingsong GUO, Fang WU, Tong YANG, Yijun SHEN